Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Catalent Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CTLT
New York
2834
https://www.catalent.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Catalent Inc
TAK or CTLT: Which Is the Better Value Stock Right Now?
- Apr 25th, 2024 3:40 pm
Charles River (CRL) Forges Collaboration With Ship of Theseus
- Apr 11th, 2024 1:10 pm
Novo Nordisk parent refiles US application on Catalent deal
- Apr 8th, 2024 10:31 am
UPDATE 1-Novo Nordisk parent refiles US application on Catalent deal
- Apr 8th, 2024 10:28 am
Ares, Blue Owl Lead $4.8 Billion Private Debt for Catalent Deal
- Apr 6th, 2024 3:08 am
13 Hot Stocks to Invest in According to Wall Street Analysts
- Mar 28th, 2024 5:15 pm
The Top 3 Pharma Stocks to Buy in March 2024
- Mar 9th, 2024 6:00 pm
HIGHLIGHTS-Novo Nordisk hopes to launch experimental obesity drug this decade
- Mar 8th, 2024 12:11 pm
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
- Mar 7th, 2024 1:00 pm
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
- Feb 10th, 2024 2:53 pm
Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down
- Feb 9th, 2024 4:28 pm
Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
- Feb 9th, 2024 2:30 pm
UPDATE 3-Catalent sales edge past estimates as focus shifts to Novo deal
- Feb 9th, 2024 2:13 pm
Catalent Inc (CTLT) Faces Headwinds with Q2 Fiscal 2024 Results
- Feb 9th, 2024 1:37 pm
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
- Feb 9th, 2024 12:59 pm
UPDATE 2-Astrazeneca says Catalent deal shows need for in-house capacity
- Feb 8th, 2024 11:37 am
Astrazeneca says Catalent deal shows need for in-house capacity
- Feb 8th, 2024 10:48 am
UPDATE 1-US FDA finds control lapses at Catalent plant being sold to Novo
- Feb 7th, 2024 5:55 pm
UPDATE 2-EU watchdog looking into impact on drug availability from Catalent-Novo deal
- Feb 7th, 2024 5:23 pm
Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings
- Feb 7th, 2024 12:51 pm
Scroll